BioCentury
ARTICLE | Clinical News

Midostaurin: Phase III data

December 14, 2015 8:00 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Midostaurin ( PKC412, CGP 41251) Business: Cancer Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135); Stem cell factor (SCF) r...